Education
About Us
Working with TipRanks
Follow Us
PharmaNutra SpA (IT:PHN)
:PHN
PHN Stock Chart & Stats
Day’s Range― - ―
52-Week Range€44.85 - €61.20
Previous CloseN/A
Volume2.81K
Average Volume (3M)13.29K
Market Cap
€485.99M
Enterprise Value€518.19M
Total Cash (Recent Filing)€14.97M
Total Debt (Recent Filing)€5.34M
Price to Earnings (P/E)29.0
Beta0.44
Next Earnings
May 12, 2025EPS Estimate
0.54Next Dividend Ex-Date
May 05, 2025Dividend Yield1.69%
Share Statistics
EPS (TTM)1.73
Shares Outstanding9,680,977
10 Day Avg. Volume8,250
30 Day Avg. Volume13,293
Financial Highlights & Ratios
PEG Ratio0.98
Price to Book (P/B)N/A
Price to Sales (P/S)5.80
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€83.00Price Target Upside63.39% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
---
PharmaNutra SpA News
PremiumCompany Announcements
PharmaNutra Expands into Canada with New Deal
PremiumCompany Announcements
PharmaNutra Reports Strong Sales Growth in ChinaPremiumCompany Announcements
PharmaNutra S.p.A. Achieves Strong Revenue Growth
PremiumCompany Announcements
PharmaNutra Expands Product Line with Innovative Supplements---
Bulls Say, Bears Say
Bulls Say
EarningsPharmaNutra released its 2024 revenue figures, reaching €115M (+15% YoY), perfectly in line with expectations.
Financial PerformanceThe analyst confirms a BUY rating with a target price of €87, suggesting a potential upside of over 60% from current prices.
Market ExpansionPharmaNutra is crafting a US market entry plan with McKinsey, aiming to drive growth through broad product applications and market insights.
Bears Say
Margin ConstraintsManagement anticipates margin constraints in 2025-26 due to increased investments.
Revenue ProjectionsThe expected tangible results from PHN USA in H2 2025 are below expectations, affecting revenue projections.
US Market ChallengesOperations in the US, launched in Q3 2023, have yet to take off, with only marginal revenue reported.
---
Options Prices
Currently, No data available
---
Ownership Overview
10.51% Insiders
0.51%
Mutual Funds
― Other Institutional Investors
88.20% Public Companies and
Individual Investors
PHN FAQ
What was PharmaNutra SpA’s price range in the past 12 months?
PharmaNutra SpA lowest stock price was €44.85 and its highest was €61.20 in the past 12 months.
What is PharmaNutra SpA’s market cap?
PharmaNutra SpA’s market cap is €485.99M.
When is PharmaNutra SpA’s upcoming earnings report date?
PharmaNutra SpA’s upcoming earnings report date is May 12, 2025 which is in 26 days.
How were PharmaNutra SpA’s earnings last quarter?
PharmaNutra SpA released its earnings results on Mar 14, 2025. The company reported €0.35 earnings per share for the quarter, missing the consensus estimate of €0.535 by -€0.185.
Is PharmaNutra SpA overvalued?
According to Wall Street analysts PharmaNutra SpA’s price is currently Undervalued.
Does PharmaNutra SpA pay dividends?
PharmaNutra SpA pays a Annually dividend of €0.85 which represents an annual dividend yield of 1.69%. See more information on PharmaNutra SpA dividends here
What is PharmaNutra SpA’s EPS estimate?
PharmaNutra SpA’s EPS estimate is 0.54.
How many shares outstanding does PharmaNutra SpA have?
PharmaNutra SpA has 9,680,977 shares outstanding.
What happened to PharmaNutra SpA’s price movement after its last earnings report?
PharmaNutra SpA reported an EPS of €0.35 in its last earnings report, missing expectations of €0.535. Following the earnings report the stock price went down -1.107%.
Which hedge fund is a major shareholder of PharmaNutra SpA?
Currently, no hedge funds are holding shares in IT:PHN
---
Company Description
PharmaNutra SpA
Pharmanutra S.p.A., a pharmaceutical and nutraceutical company, researches, designs, develops, and markets nutritional supplements and medical devices in Italy, rest of Europe, the Middle East, Far East, and internationally. The company also produces and markets pharmaceuticals, medical devices, OTC products, and nutraceuticals for pediatric sector; and produces and distributes raw materials and active ingredients for the food, pharmaceutical, and food supplement industries. Its products primarily include SiderAL, SiderAL Forte, SiderAL Folic, Cardio SiderAL, SiderAL Med, Cetilar Crema, Cetilar Patch, Tape, ApportAL, UltraMag, Gestalys DHA, Novomega, Bonecal, and DiKappa 2. The company distributes and sells its products through sales representatives, wholesalers, pharmacies, and para-pharmacies. Pharmanutra S.p.A. was founded in 2003 and is based in Pisa, Italy.
---
PHN Stock 12 Month Forecast
Average Price Target
€83.00
▲(63.39% Upside)
Technical Analysis
Best Analysts Covering PHN
1 Year
1 Year Success Rate
4/9 ratings generated profit
1 Year Average Return
-2.54%
reiterated a buy rating last month
Copying Giorgio Tavolini's trades and holding each position for 1 Year would result in 44.44% of your transactions generating a profit, with an average return of -2.54% per trade.
---